Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem, vol.48, pp.6523-6543, 2005. ,
Multi-target therapeutics: when the whole is greater than the sum of the parts, Drug Discov. Today, vol.12, pp.34-42, 2007. ,
Designing multiple ligands-medicinal chemistry strategies and challenges, Curr. Pharmaceut. Des, vol.15, pp.587-600, 2009. ,
DOI : 10.2174/138161209787315594
Shifting from the single to the multitarget paradigm in drug discovery, Drug Discov. Today, vol.18, pp.495-501, 2013. ,
Polypharmacology-foe or friend?, J. Med. Chem, vol.56, pp.8955-8971, 2013. ,
Polypharmacology: challenges and opportunities in drug discovery, J. Med. Chem, vol.57, pp.7874-7887, 2014. ,
Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids, Eur. J. Med. Chem, vol.77, pp.422-487, 2014. ,
Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment, Proc. Natl. Acad. Sci. Unit. States Am, vol.111, pp.3825-3830, 2014. ,
Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride, J. Med. Chem, vol.58, pp.3172-3187, 2015. ,
Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties, Eur. J. Med. Chem, vol.93, pp.42-50, 2015. ,
The emergence of designed multiple ligands for neurodegenerative disorders, Prog. Neurobiol, vol.94, pp.347-359, 2011. ,
Metabolic syndrome: definition, pathophysiology, and mechanisms, Am. Heart J, vol.149, pp.33-45, 2005. ,
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy, Nat. Rev. Drug Discov, vol.5, pp.295-309, 2006. ,
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system, J. Hypertens, vol.22, pp.2253-2261, 2004. ,
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-activity, Circulation, vol.109, pp.2054-2057, 2004. ,
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity, Hypertension, vol.43, pp.993-1002, 2004. ,
Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator, Acta Diabetol, vol.42, pp.9-16, 2005. ,
Structural basis for telmisartan-mediated partial activation of PPAR gamma, Hypertens. Res, vol.35, pp.715-719, 2012. ,
Telmisartan improves insulin resistance: a meta-analysis, Am. J. Therapeut, 2018. ,
DOI : 10.1097/mjt.0000000000000733
Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome, J. Med. Chem, vol.53, pp.1076-1085, 2010. ,
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-?, J. Med. Chem, vol.54, pp.4219-4233, 2011. ,
Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-?, Bioorg. Med. Chem. Lett, vol.23, pp.767-772, 2013. ,
Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR? agonists, Bioorg. Med. Chem. Lett, vol.24, pp.1098-1103, 2014. ,
Design, synthesis, and docking studies of novel telmisartan-glitazone hybrid analogs for the treatment of metabolic syndrome, Med. Chem. Res, vol.18, pp.589-610, 2009. ,
,
Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage, J. Med. Chem, vol.52, pp.7220-7227, 2009. ,
New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: ester, amide and amine linkers, Eur. J. Med. Chem, vol.50, pp.90-101, 2012. ,
New no-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties, J. Med. Chem, vol.49, pp.2628-2639, 2006. ,
A novel series of (Phenoxyalkyl)imidazoles as potent H3-Receptor histamine antagonists, J. Med. Chem, vol.39, pp.3806-3813, 1996. ,
Peroxisome proliferator-activated receptor-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells, Mol. Pharmacol, vol.67, pp.1342-1348, 2005. ,
A convenient synthesis by microwave irradiation of an active metabolite (EXP-3174) of losartan, Tetrahedron Lett, vol.44, pp.2835-2841, 2003. ,
,
,
A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) ? agonists: design and synthesis of benzylpyrazole acylsulfonamides, Bioorg. Med. Chem, vol.20, pp.714-733, 2012. ,
Synthesis and biological activity of Benzoxazole containing thiazolidinedione derivatives, Arch Pharm. Res. (Seoul), pp.1099-1105, 2004. ,
,
,
Benzoylphenyl)-l-tyrosine PPAR? agonists. 3. Structure?Activity relationship and optimization of the N-Aryl substituent, J. Med. Chem, vol.41, issue.2, pp.5055-5069, 1998. ,
Intramolecular asymmetric amidations of sulfonamides and sulfamates catalyzed by chiral dirhodium (II) complexes, Helv. Chim. Acta, vol.87, pp.1607-1615, 2004. ,
DOI : 10.1002/hlca.200490148
Regulation of peroxisome proliferator-activated receptor activity by losartan metabolites, Hypertension, vol.47, pp.586-589, 2006. ,
Catalytic nucleophilic fluorination by an imidazolium ionic liquid possessing trialkylphosphine oxide functionality, J. Fluorine Chem, vol.178, pp.47-55, 2015. ,
DOI : 10.1016/j.jfluchem.2015.06.022
Synthesis and anti-proliferative activity of new biphenyle-benzylidenethiazolidine-2,4-dione bis-adducts containing various heterocyclic cores, Lett. Drug Des. Discov, vol.11, pp.256-264, 2014. ,
DOI : 10.2174/15701808113106660080
URL : https://hal.archives-ouvertes.fr/hal-01094215
Highly efficient synthesis of ?,?-acetylenic aldehydes from terminal alkynes using DMF as the formylating reagent, Tetrahedron Lett, vol.39, issue.98, pp.1352-1357, 1998. ,
Highly efficient and mild synthesis of variously 5-substituted-4-carbaldehyde-1,2,3-triazole derivatives, Tetrahedron Lett, vol.42, pp.1923-1925, 2001. ,
Microwave-assisted intramolecular huisgen cycloaddition of azido alkynes derived from ?-amino acids, J. Org. Chem, vol.74, pp.1314-1321, 2009. ,
Benzoylphenyl)-l-tyrosine PPAR? agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents, J. Med. Chem, vol.41, issue.2, pp.5020-5036, 1998. ,
Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives, J. Med. Chem, vol.34, pp.2525-2547, 1991. ,
Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators, Biochim. Biophys. Acta BBA-Mol. Cell Biol. Lipids, vol.1771, pp.915-925, 2007. ,
LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, J. Chem. Inf. Model, vol.51, pp.2778-2786, 2011. ,
Differential activity of rosiglitazone enantiomers at PPAR?, Bioorg. Med. Chem. Lett, vol.8, pp.664-671, 1998. ,
Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis, Diabetes Metab, vol.38, pp.475-484, 2012. ,
Study of novel anticancer 4-thiazolidinone derivatives, Chem. Biol. Interact, vol.262, pp.46-56, 2017. ,
Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPAR?), Eur. J. Med. Chem, vol.141, pp.162-168, 2017. ,
Erosion of the chronic myeloid leukaemia stem cell pool by PPAR? agonists, Nature, vol.525, pp.380-383, 2015. ,
Reprofiling of troglitazone towards more active and less toxic derivatives: a new hope for cancer treatment?, Curr. Top. Med. Chem, vol.16, pp.2115-2124, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01281602
Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study, Eur. J. Med. Chem, vol.51, pp.206-215, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00746870
New losartan derivatives with potential dual activity as angiotensin II receptor blocker and peroxisome proliferator activated receptor gamma activator, Ann. Cardiol. Angeiol, vol.61, pp.11-12, 2012. ,
NMR chemical shifts of common laboratory solvents as trace impurities, J. Org. Chem, vol.62, pp.7512-7515, 1997. ,
AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comput. Chem, vol.30, pp.2785-2791, 2009. ,
Reduced surface: an efficient way to compute molecular surfaces, Biopolymers, vol.38, pp.1097-0282, 1996. ,
, The PyMOL Molecular Graphics System, 2015.